bluebird, Reata, Catalent raise over $1 billion across follow-ons

bluebird bio Inc. (NASDAQ:BLUE), Reata Pharmaceuticals Inc. (NASDAQ:RETA) and Catalent Inc. (NYSE:CTLT) each priced follow-ons late July 24, together raising more than $1 billion.

bluebird raised $550 million through the sale of 3.4 million shares at $162.50 in an up-sized follow-on underwritten by Goldman Sachs, BofA Merrill Lynch, J.P. Morgan and Cowen. The price is an 8% discount to bluebird's $177.25 close on July 23, before it proposed after market hours to raise $400 million. bluebird slipped $13.60 to $163.65 on July 24, and added $8.85 to $172.50 July 25...